127 related articles for article (PubMed ID: 37832700)
21. Applicability and Limitations of Cell-Penetrating Peptides in Noncovalent Mucosal Drug or Carrier Delivery Systems.
Kamei N; Bech Nielsen EJ; Nakakubo T; Aoyama Y; Rahbek UL; Pedersen BL; Takeda-Morishita M
J Pharm Sci; 2016 Feb; 105(2):747-753. PubMed ID: 26869427
[TBL] [Abstract][Full Text] [Related]
22. Low molecular weight chitosan nanoparticles as new carriers for nasal vaccine delivery in mice.
Vila A; Sánchez A; Janes K; Behrens I; Kissel T; Vila Jato JL; Alonso MJ
Eur J Pharm Biopharm; 2004 Jan; 57(1):123-31. PubMed ID: 14729088
[TBL] [Abstract][Full Text] [Related]
23. Usefulness of cell-penetrating peptides and penetration accelerating sequence for nose-to-brain delivery of glucagon-like peptide-2.
Akita T; Kimura R; Akaguma S; Nagai M; Nakao Y; Tsugane M; Suzuki H; Oka JI; Yamashita C
J Control Release; 2021 Jul; 335():575-583. PubMed ID: 34116136
[TBL] [Abstract][Full Text] [Related]
24. Performance of cell-penetrating peptide-linked polymers physically mixed with poorly membrane-permeable molecules on cell membranes.
Sakuma S; Suita M; Yamamoto T; Masaoka Y; Kataoka M; Yamashita S; Nakajima N; Shinkai N; Yamauchi H; Hiwatari K; Hashizume A; Tachikawa H; Kimura R; Ishimaru Y; Kasai A; Maeda S
Eur J Pharm Biopharm; 2012 May; 81(1):64-73. PubMed ID: 22306700
[TBL] [Abstract][Full Text] [Related]
25. [Construction of artesunate nanoparticles modified by hyaluronic acid and cell-penetrating peptides and its inhibitory effect on cancer cells in vitro].
Li J; Jin S; Dong XR; Han XF; Wang MY
Zhongguo Zhong Yao Za Zhi; 2018 Sep; 43(18):3668-3675. PubMed ID: 30384531
[TBL] [Abstract][Full Text] [Related]
26. Efficacy, safety and mechanism of cyclodextrins as absorption enhancers in nasal delivery of peptide and protein drugs.
Marttin E; Verhoef JC; Merkus FW
J Drug Target; 1998; 6(1):17-36. PubMed ID: 9769018
[TBL] [Abstract][Full Text] [Related]
27. Effect of aminated gelatin on the nasal absorption of insulin in rats.
Seki T; Kanbayashi H; Nagao T; Chono S; Tomita M; Hayashi M; Tabata Y; Morimoto K
Biol Pharm Bull; 2005 Mar; 28(3):510-4. PubMed ID: 15744079
[TBL] [Abstract][Full Text] [Related]
28. Quantitative estimation of drug permeation through nasal mucosa using in vitro membrane permeability across Calu-3 cell layers for predicting in vivo bioavailability after intranasal administration to rats.
Inoue D; Furubayashi T; Tanaka A; Sakane T; Sugano K
Eur J Pharm Biopharm; 2020 Apr; 149():145-153. PubMed ID: 32057906
[TBL] [Abstract][Full Text] [Related]
29. Noninvasive insulin delivery: the great potential of cell-penetrating peptides.
Kamei N; Nielsen EJ; Khafagy el-S; Takeda-Morishita M
Ther Deliv; 2013 Mar; 4(3):315-26. PubMed ID: 23442079
[TBL] [Abstract][Full Text] [Related]
30. Modified nanoparticles with cell-penetrating peptide and amphipathic chitosan derivative for enhanced oral colon absorption of insulin: preparation and evaluation.
Guo F; Zhang M; Gao Y; Zhu S; Chen S; Liu W; Zhong H; Liu J
Drug Deliv; 2016 Jul; 23(6):2003-14. PubMed ID: 26181840
[TBL] [Abstract][Full Text] [Related]
31. Enhanced intranasal insulin delivery by formulations and tumor protein-derived protein transduction domain as an absorption enhancer.
Kim NA; Thapa R; Jeong SH; Bae HD; Maeng J; Lee K; Park K
J Control Release; 2019 Jan; 294():226-236. PubMed ID: 30557648
[TBL] [Abstract][Full Text] [Related]
32. Improved nasal absorption of drugs using poly-L-arginine: effects of concentration and molecular weight of poly-L-arginine on the nasal absorption of fluorescein isothiocyanate-dextran in rats.
Miyamoto M; Natsume H; Iwata S; Ohtake K; Yamaguchi M; Kobayashi D; Sugibayashi K; Yamashina M; Morimoto Y
Eur J Pharm Biopharm; 2001 Jul; 52(1):21-30. PubMed ID: 11438420
[TBL] [Abstract][Full Text] [Related]
33. Scalable production of core-shell nanoparticles by flash nanocomplexation to enhance mucosal transport for oral delivery of insulin.
He Z; Liu Z; Tian H; Hu Y; Liu L; Leong KW; Mao HQ; Chen Y
Nanoscale; 2018 Feb; 10(7):3307-3319. PubMed ID: 29384554
[TBL] [Abstract][Full Text] [Related]
34. Brain delivery of insulin boosted by intranasal coadministration with cell-penetrating peptides.
Kamei N; Takeda-Morishita M
J Control Release; 2015 Jan; 197():105-10. PubMed ID: 25445695
[TBL] [Abstract][Full Text] [Related]
35. Rapid-onset intranasal delivery of metoclopramide hydrochloride Part II: Safety of various absorption enhancers and pharmacokinetic evaluation.
Zaki NM; Mortada ND; Awad GA; Abd ElHady SS
Int J Pharm; 2006 Dec; 327(1-2):97-103. PubMed ID: 16959453
[TBL] [Abstract][Full Text] [Related]
36. Analysis of transient and reversible effects of poly-L-arginine on the in vivo nasal absorption of FITC-dextran in rats.
Ohtake K; Natsume H; Ueda H; Morimoto Y
J Control Release; 2002 Aug; 82(2-3):263-75. PubMed ID: 12175742
[TBL] [Abstract][Full Text] [Related]
37. Hydrolysis of leucine enkephalin in the nasal cavity of the rat--a possible factor in the low bioavailability of nasally administered peptides.
Hussain A; Faraj J; Aramaki Y; Truelove JE
Biochem Biophys Res Commun; 1985 Dec; 133(3):923-8. PubMed ID: 4084310
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of Cell-Penetrating Peptides as Versatile, Effective Absorption Enhancers: Relation to Molecular Weight and Inherent Epithelial Drug Permeability.
Kamei N; Yamanaka J; Oda Y; Kaneoka S; Koide Y; Haruna Y; Takahashi Y; Tamiwa H; Takeda-Morishita M
Pharm Res; 2020 Sep; 37(10):182. PubMed ID: 32888051
[TBL] [Abstract][Full Text] [Related]
39. In situ gels of Metoclopramide Hydrochloride for intranasal delivery: in vitro evaluation and in vivo pharmacokinetic study in rabbits.
Mahajan HS; Gattani S
Drug Deliv; 2010 Jan; 17(1):19-27. PubMed ID: 19958151
[TBL] [Abstract][Full Text] [Related]
40. Positively charged polyethylenimines enhance nasal absorption of the negatively charged drug, low molecular weight heparin.
Yang T; Hussain A; Bai S; Khalil IA; Harashima H; Ahsan F
J Control Release; 2006 Oct; 115(3):289-97. PubMed ID: 17023085
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
